格隆汇11月5日丨希玛医疗(03309.HK)公告，11月5日耗资36.6万港元回购20.4万股。 ...

Core Viewpoint - The company, Hema Medical (03309), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Group 1 - The company will spend HKD 366,400 to repurchase 204,000 shares [1] - The buyback price per share ranges from HKD 1.79 to HKD 1.81 [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 希瑪醫療控股有限公司 呈交日期： 2025年11月5日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 03309 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | | 已發行股份總數 | | | | 已發行股份（不包括庫存股份）數 目 ...

Summary of Key Points Core Viewpoint - On November 4, 38 Hong Kong-listed companies conducted share buybacks, totaling 62.68 million shares and an aggregate amount of HKD 294 million [1][2]. Group 1: Buyback Details - China Feihe repurchased 18 million shares for HKD 76.11 million, with a highest price of HKD 4.260 and a lowest price of HKD 4.210, bringing its total buyback amount for the year to HKD 233 million [1][2]. - COSCO Shipping Holdings repurchased 4.5 million shares for HKD 61.70 million, with a highest price of HKD 13.960 and a lowest price of HKD 13.600, accumulating a total buyback amount of HKD 45.30 billion for the year [1][2]. - Pacific Shipping repurchased 10 million shares for HKD 26.09 million, with a highest price of HKD 2.640 and a lowest price of HKD 2.580, totaling HKD 22.91 million in buybacks for the year [1][2]. Group 2: Notable Companies - The largest buyback amount on November 4 was by China Feihe at HKD 76.11 million, followed by COSCO Shipping Holdings at HKD 61.70 million [1][2]. - In terms of share quantity, China Feihe led with 18 million shares repurchased, followed by Pacific Shipping with 10 million shares and Sinopec with 5.15 million shares [1][2]. - Noteworthy is that companies like Fenbi and Taimei Medical Technology conducted their first buybacks of the year on this date [2].

Core Viewpoint - Hema Medical (03309.HK) announced a share buyback of approximately HKD 537,100 for 300,000 shares at a price range of HKD 1.77-1.81 per share, indicating a strategic move to enhance shareholder value [1] Company Summary - As of November 4, 2025, Hema Medical's stock closed at HKD 1.81, down 0.55%, with a trading volume of 936,000 shares and a turnover of HKD 1.6597 million [1] - The company has a market capitalization of HKD 2.259 billion, ranking 15th in the medical services sector [1] Industry Summary - Hema Medical's key financial metrics compared to the industry average are as follows: - Return on Equity (ROE): -6.36% vs. industry average of -0.02%, ranking 39th [1] - Market capitalization: HKD 2.259 billion vs. industry average of HKD 7.906 billion, ranking 15th [1] - Revenue: HKD 1.935 billion vs. industry average of HKD 3.832 billion, ranking 15th [1] - Net Profit Margin: 5.95% vs. industry average of -843.36%, ranking 25th [1] - Gross Profit Margin: 31.12% vs. industry average of 39.76%, ranking 28th [1] - Debt Ratio: 29.8% vs. industry average of 74.15%, ranking 21st [1] - There has been low attention from investment banks, with no ratings given in the past 90 days [1]

格隆汇11月4日丨希玛医疗(03309.HK)发布公告，2025年11月4日耗资53.71万港元回购30万股，回购价 格每股1.77-1.81港元。 ...

Core Viewpoint - The company, Hema Medical (03309), announced a share buyback plan, indicating confidence in its stock value and future prospects [1] Summary by Category Company Actions - Hema Medical plans to repurchase approximately 300,000 shares at a total cost of about HKD 537,100 [1] - The buyback price is set between HKD 1.77 and HKD 1.81 per share [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 希瑪醫療控股有限公司 呈交日期： 2025年11月4日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 03309 | 說明 | | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | 事件 | 已發行股份（不包括庫存股份）變動 | | | 庫存股份變動 | 每股發行/出售價 (註4) | 已發行股份總數 | | | | 已發行 ...

Core Viewpoint - Hema Medical (03309.HK) announced a share buyback of 320,000 shares for a total cost of HKD 579,000 on November 3, 2025, indicating a strategic move to enhance shareholder value [1] Company Summary - Hema Medical's stock closed at HKD 1.82 on November 3, 2025, remaining unchanged from the previous trading day, with a trading volume of 1.19 million shares and a turnover of HKD 2.1346 million [1] - The company has a market capitalization of HKD 2.26 billion, ranking 15th in the medical services sector [1] Financial Metrics - Return on Equity (ROE) stands at -6.36%, significantly lower than the industry average of 0.02%, ranking 39th out of 60 [1] - The circulating market value in Hong Kong is HKD 22.6 billion, compared to the industry average of HKD 78.25 billion, ranking 15th out of 60 [1] - Revenue is reported at HKD 19.35 billion, below the industry average of HKD 38.32 billion, also ranking 15th out of 60 [1] - Net profit margin is at 5.95%, contrasting sharply with the industry average of -843.36%, ranking 25th out of 60 [1] - Gross profit margin is 31.12%, lower than the industry average of 39.76%, ranking 28th out of 60 [1] - Debt ratio is 29.8%, significantly better than the industry average of 74.15%, ranking 21st out of 60 [1]

Core Viewpoint - The company, 希玛医疗 (03309), announced a share buyback plan, indicating confidence in its financial position and future prospects [1] Group 1 - The company will spend HKD 579,000 to repurchase 320,000 shares [1]